HIV Market has Strong Competition Between Several Marketed and Combination Products

HIV AIDS - Drug Pipeline Analysis and Marketdrugs compete on efficacy in terms of delaying the
Forecasts to 2016progression of the disease and combination drugs are
 considered far better in this regard. The drugs on the
 This report provides the key data, information andmarket today aim to prolong the time it takes for
analysis on the HIV/AIDS market. The reportthe HIV infection to become AIDS. This has led to an
provides a comprehensive overview of the annualizedincrease in the average life expectancy of people
market data from 2001 to 2009, and forecast seveninfected with HIV. Overall, the HIV/AIDS market is in
years to 2016. The research also includes marketneed of products with better efficacy profiles and
characterization, opportunities, the unmet needsthose which promise to cure the disease.
associated with HIV/AIDS, competitive assessment, 
the product profiles of the major marketed products The Unmet Need of a Cost Effective Cure is
and the promising drugs in the pipeline, an overviewUnlikely to be Fulfilled in the Coming Years
of the discontinued projects, the implications for It has found that the global HIV/AIDS market is a
future market competition, and the key players inhighly lucrative market with high levels of unmet need
the HIV/AIDS market. ( )in terms of drug efficacy and curing the disease. The
 HIV market consists of a large number of drugs that
 The HIV/AIDS Therapeutics Market is Forecast toare approved for HIV but none that can cure the
Show Moderate Growth To 2016disease. All these drugs need long term usage and
 This analysis suggests that the global Humanthe length of the therapy can last approximately 20
Immunodeficiency Virus (HIV)/Acquired Immuneyears. The HIV drugs on the market are considered
Deficiency Syndrome (AIDS) market was worth $12safe as the side effects associated with HIV drugs
billion in 2009. It is forecast to grow at a Compoundare minimal when compared with the effects of the
Annual Growth Rate (CAGR) of 2% for the nextuntreated progression of the disease itself. The
seven years to reach $13.7 billion by 2016. The globaldisease can be fatal and is associated with many
HIV infection market will continue to grow betweenopportunistic infections which decrease the quality of
2009 and 2016 at a moderate rate due to a series oflife of the infected person. Therefore, while the
patent expiries in this period. The growth rate is likelyunmet need for the HIV market will remain, some
to decline from 2012 onwards due to the impact ofnewer drugs may offer better treatment for
patent expiries of key drugs. However, migration todrug-resistance HIV or have better efficacy in terms
new branded drugs is likely to minimize the impact ofof lower dosage frequencies to improve patient
generics. This moderate growth will be driven by ancompliance and improve treatment quality in the
increasing prescription rate and increased usage ofcoming years.
newer drugs such as Atripla as part of Highly Active 
Antiretroviral Therapy (HAART).The number of Strong Clinical Pipeline with Several First-in-Class
people taking treatment for HIV is increasing and theMolecules
average annual cost of therapy for Antiretroviral It analyzed the HIV/AIDS pipeline and found it to
Treatment (ART) is forecast to increase at a higherbe strong. The pipeline for HIV consists of more than
rate over the next two years with an expected250 molecules currently in development for various
price decline from 2012 onwards due to a series ofdisease segments. There are many companies active
patent expirations. The market is characterized by ain developing HIV drugs. In addition to the leading
high unmet need of drugs in terms of efficacy andmarket players, Boehring Ingelheim, Achillion
drugs which can cure the disease. HAART requiresPharmaceuticals, GlaxoSmithKline, Incyte and
patients to take different classes of drugs and hasPharmasset, Shire Pharmaceuticals and Tibotec Virco
succeeded in achieving near zero levels of HIV inare active in developing drugs for the HIV
infected people however. The increased uptake oftherapeutics market. The pipeline for HIV/AIDS is
HAART and increasing awareness will drive thestrong as many pharmaceutical companies today are
market. Therefore despite challenges such as the lackprimarily focusing on the new antiviral agents which
of a cure and the risk of building drug resistance tooffer effective treatment options for patients who
current marketed drugs, the HIV market will continueno longer respond to existing therapies. As a result,
to grow at a moderate rate.the treatment paradigm for HIV has evolved from
 monotherapy to triple combination treatment known
 The HIV Market has Strong Competition Betweenas HAART. The HIV/AIDS clinical pipeline is strong
Several Marketed and Combination Productswith several first-in-class molecules in development.
 It analyzed the current competitive landscape forNucleoside Reverse Transcriptase Inhibitors (NRTIs),
HIV/AIDS drugs and found the competition to beNon-Nucleoside Reverse Transcriptase Inhibitors
strong. There are more than 30 marketed products(NNRTIs) and protease inhibitors are most popular
from different classes of therapies for the treatmentdrug classes in which most pipeline activity is currently
of HIV. However, all these classes of drugs aretaking place. Overall, there are 101 first-in-class
relatively high on safety but moderate on efficacy.molecules which accounts for 41% of the pipeline.
This is because there is no cure for the infection onMulti-class combination therapies and me-too products
the market. In addition, some of the new multi-classaccount for approximately 42% of the clinical pipeline
combination drugs have improved the efficacy inand are expected to improve on the safety profiles
terms of lowering HIV levels in the body. Thereforeof marketed drugs.